Abvc Biopharma (ABVC) Assets Average (2011 - 2026)
Abvc Biopharma's (ABVC) quarterly Assets Average came in at $20.4 million in Q1 2026, up 168.21% YoY from $7.6 million in Q1 2025, and down 3.5% on a QoQ basis from $21.1 million in Q4 2025.
Abvc Biopharma (ABVC) Assets Average (2011 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 14 years of Assets Average data on file, last reported at $20.4 million in Q1 2026.
- Quarterly Assets Average rose 168.21% year-over-year to $20.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.4 million (up 168.21% YoY) and the FY2025 annual result came in at $14.3 million, up 100.74% from the prior year.
- Assets Average slipped to $20.4 million in Q1 2026, from $21.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $21.1 million in Q4 2025 to a low of $7.3 million in Q1 2024.
- A 5-year average of $11.5 million and a median of $10.2 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average sank 38.94% — and 2025, when it surged 176.0%.
- Tracing ABVC's Assets Average over 5 years: stood at $10.0 million in 2022, then climbed by 16.15% to $11.6 million in 2023, then tumbled by 34.26% to $7.7 million in 2024, then surged by 176.0% to $21.1 million in 2025, then declined by 3.5% to $20.4 million in 2026.
- The last three Assets Average figures came in at $20.4 million (Q1 2026), $21.1 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | 19.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.57 Mn |
| Mar 31, 2026 | 20.40 Mn |
| Dec 31, 2025 | 21.14 Mn |
| Sep 30, 2025 | 14.44 Mn |
| Jun 30, 2025 | 7.67 Mn |
| Mar 31, 2025 | 7.60 Mn |
| Dec 31, 2024 | 7.66 Mn |
| Sep 30, 2024 | 7.91 Mn |
| Jun 30, 2024 | 8.01 Mn |
| Mar 31, 2024 | 7.34 Mn |
| Dec 31, 2023 | 11.65 Mn |
| Sep 30, 2023 | 12.96 Mn |
| Jun 30, 2023 | 10.03 Mn |
| Mar 31, 2023 | 10.16 Mn |
| Dec 31, 2022 | 10.03 Mn |
| Sep 30, 2022 | 12.13 Mn |
| Jun 30, 2022 | 12.92 Mn |
| Mar 31, 2022 | 12.88 Mn |
| Dec 31, 2021 | 13.03 Mn |
| Sep 30, 2021 | 10.65 Mn |